Indivior Pharmaceuticals, Inc. (INDV) EBITDA
- 2026-06-30: Basis Reported; EBITDA $162.00M*; Operating income $160.00M; Depreciation and amortization $2.00M*.
- 2026-03-31: Basis Reported; EBITDA $139M; Operating income (m); Depreciation and amortization (m).
- 2025-12-31: Basis Reported; EBITDA $83M; Operating income (m); Depreciation and amortization (m).
- 2025-09-30: Basis Reported; EBITDA $46.00M*; Operating income $43.00M; Depreciation and amortization $3.00M*.
Complete source-backed ebitda history.
- Available history
- 2022-12-31 to 2026-03-31
- Data captured
Historical EBITDA
EBITDA 3 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2026-06-30 | Reported | $162.00M* | $160.00M | $2.00M* | $343.00M | 47.23%* | $7.00M* | $229.00M* | $50.00M | (m) | $122.00M | $38.00M |
|---|
| 2026-03-31 | Reported | $139M | (m) | (m) | (m) | 43.85% | $20.00M | -$9.00M | $40.00M | (m) | $124.00M | $26.00M |
|---|
| 2025-12-31 | Reported | $83M | (m) | (m) | (m) | 23.18% | (m) | (m) | (m) | (m) | (m) | (m) |
|---|
| 2025-09-30 | Reported | $46.00M* | $43.00M | $3.00M* | $314.00M | 14.65%* | $20.00M* | -$39.00M* | $83.00M | (m) | $155.00M | -$5.00M |
|---|
| 2025-06-30 | Reported | $74.00M* | $72.00M | $2.00M* | $302.00M | 24.50%* | $17.00M* | $158.00M* | $52.00M | (m) | $158.00M | $44.00M |
|---|
| 2025-03-31 | Reported | $69M | (m) | (m) | (m) | 25.94% | $5.00M | $75.00M | $44.00M | (m) | $133.00M | $11.00M |
|---|
| 2024-12-31 | Reported | $51M | (m) | (m) | (m) | 17.06% | (m) | (m) | (m) | (m) | $175.00M | $17.00M |
|---|
| 2024-09-30 | Reported | $39.00M* | $35.00M | $4.00M* | $307.00M | 12.70%* | $7.00M* | $2.00M* | $66.00M | (m) | $142.00M | $8.00M |
|---|
| 2024-06-30 | Reported | -$116.00M* | -$118.00M | $2.00M* | $299.00M | -38.80%* | $4.00M* | $88.00M* | $79.00M | (m) | $152.00M | -$23.00M |
|---|
| 2024-03-31 | Reported | $80M | (m) | (m) | (m) | 28.17% | $2.00M | -$37.00M | $38.00M | (m) | $143.00M | $11.00M |
|---|
EBITDA 12 month
| Date | Basis | EBITDA | Operating income | Depreciation and amortization | Revenue | EBITDA margin | Capital spending | Operating cash flow | Cost of products and services | Research and development | Selling, general and administration | Income tax expense / benefit |
|---|
| 2025-12-31 | Reported | $272M | (m) | (m) | (m) | 21.95% | $66.00M | -$27.00M | $246.00M | (m) | $634.00M | $29.00M |
|---|
| 2025-09-30 | Rolling | (m) | $227.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $621.00M* | $67.00M* |
|---|
| 2025-06-30 | Rolling | (m) | $219.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $608.00M* | $80.00M* |
|---|
| 2025-03-31 | Rolling | (m) | $29.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $602.00M* | $13.00M* |
|---|
| 2024-12-31 | Reported | $54M | (m) | (m) | (m) | 4.55% | $29.00M | $36.00M | $231.00M | (m) | $612.00M | $13.00M |
|---|
| 2024-12-31 | Rolling | (m) | $38.00M* | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $612.00M* | $13.00M* |
|---|
| 2023-12-31 | Reported | -$137M | (m) | (m) | (m) | -12.53% | $8.00M | -$300.00M | $174.00M | (m) | $565.00M | -$19.00M |
|---|
| 2022-12-31 | Reported | -$65M | (m) | (m) | (m) | -7.21% | $5.00M | -$4.00M | $151.00M | (m) | $466.00M | -$43.00M |
|---|